Genome-wide meta-analysis identifies novel maternal risk variants and enables polygenic prediction of preeclampsia and gestational hypertension

Competing Interest Statement

M.C.H. reports consulting fees from CRISPR Therapeutics, advisory board service for Miga Health, and grant support from Genentech, all unrelated to this work. K.J.G. has served as a consultant for BillionToOne, Aetion, and Roche for projects unrelated to this work. R.S. is a co-founder of Magnet Biomedicine, unrelated to this work. R.D. reports receiving grants from AstraZeneca, grants and nonfinancial support from Goldfinch Bio, being a scientific co-founder, consultant, and equity holder for Pensieve Health (pending), and being a consultant for Variant Bio, all unrelated to this work. P.N. reports grant support from Amgen, Apple, AstraZeneca, Boston Scientific, and Novartis, spousal employment and equity at Vertex, consulting income from Apple, AstraZeneca, Novartis, Genentech / Roche, Blackstone Life Sciences, Foresite Labs, and TenSixteen Bio, and is a scientific advisor board member and shareholder of TenSixteen Bio and geneXwell, all unrelated to this work.

Funding Statement

This work was supported by grants from the U.S. National Heart Lung and Blood Institute K08HL166687 (M.C.H.), K08HL146963 (K.J.G.), R01 HL163234 (R.S., K.J.G.), R01HL139865 (R.D.), R01HL155915 (R.D.), DP2HL152423 (R.M.G.), U01HL166060 (R.M.G.), R03HL148483 (R.M.G.), R01HL142711 (P.N.), R01HL127564 (P.N.), R01HL148050 (P.N.), R01HL151283 (P.N.), R01HL148565 (P.N.), R01HL135242 (P.N.), R01HL151152 (P.N.); the American Heart Association 940166 (M.C.H.), 979465 (M.C.H.); the Korea Health Industry Development Institute HI19C1330 (S.M.J.C.); Harvard Catalyst Medical Research Investigator Training Program (A.P.P.); National Human Genome Research Institute U01HG011719 (A.P.P. and P.N.); the Belgian American Educational Foundation (A.S.); the U.S. National Institute of General Medical Sciences R35GM147197 (R.F.G.), R35GM124836 (R.D.); National Institute of Diabetes and Digestive and Kidney Diseases R01DK125782 (P.N.); National Institute of Child Health and Human Development R01HD101246 (D.M.H.); Preeclampsia Foundation (K.J.G., R.S.); Fondation Leducq TNE-18CVD04 (P.N.); and the Massachusetts General Hospital Paul and Phyllis Fireman Endowed Chair in Vascular Medicine (P.N.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

FinnGen was approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District. The Estonian Committee on Bioethics gave ethical approval for the work conducted in the Estonian Biobank. The South East Research Ethics Committee gave ethical approval for the work conducted in Genes & Health. The University of Michigan Medical School Institutional Review Board gave ethical approval for the analyses conducted in the Michigan Genomics Initiative. The Mass General Brigham Institutional Review Board gave ethical approval for the work conducted in the Mass General Brigham Biobank. Biobank Japan received ethics approval from the Institute of Medical Science, the University of Tokyo, the RIKEN Yokohama Institute, and all participating hospitals. BioMe received ethics approval from the Icahn School of Medicine at Mt. Sinai Institutional Review Board. We used publicly available summary statistics for discovery GWAS from the InterPregGen consortium; all contributing studies received ethics approval as reported previously17. The work conducted in HUNT was approved by the Regional Committee for Ethics in Medical Research, Norway (2018/2488). The Penn Medicine Biobank received ethics approval from the University of Pennsylvania Institutional Review Board. The North West Multi-centre Research Ethics Committee approved the UK Biobank; the Mass General Brigham Institutional Review Board approved secondary data analyses of the UK Biobank (application #7089). The nuMoM2b study was approved by the institutional review boards of each participating site. All participants in all studies contributing data for this study signed informed consent for participation and the use of data in research.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes